ClinicalTrials.gg
CompletedNCT04348305COVID STEROIDUpdated Sep 21, 2021

Hydrocortisone for COVID-19 and Severe Hypoxia

A Phase 3 interventional study of Hydrocortisone and Sodium Chloride 9mg/mL in Covid-19 and Hypoxia, sponsored by Scandinavian Critical Care Trials Group. Completed at 14 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Scandinavian Critical Care Trials Group · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 99 studies in COVID-19 with a site in Denmark — 10 open to participants now, 12 under way, 3 of them phase 3. COVID-19 · Denmark.

Enrollment
48th of 55
30 · median 317
Started
2020
with 54 others
Phase 3
25 of 99
3 open now
Registered
10th of 99
by date

Among the 99 studies in COVID-19 with a site in Denmark, this one is the 48th largest by enrollment of the 55 interventional ones that give a count, is one of 55 that started in 2020, is one of 25 in phase 3, and was the 10th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

10 of the 99 studies in COVID-19 with a site in Denmark are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in COVID-19 with a site in Denmark, or all of them as a file.
02

Study summary

We aim to assess the benefits and harms of low-dose hydrocortisone in patients with COVID-19 and severe hypoxia.

Read the detailed description

Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic of coronavirus disease (COVID-19) with many patients developing severe hypoxic respiratory failure. Many patients have died, and healthcare systems in several countries have been or will be overwhelmed because of a surge of patients needing hospitalisation and intensive care. There is no proven treatment for COVID-19; the care is supportive, including respiratory and circulatory support. For other patient groups with similar critical illness (acute respiratory disease syndrome and septic shock), corticosteroids are used because they reduce the duration of mechanical ventilation, length of stay in the intensive care unit, and potentially also mortality. Corticosteroids have been used in some patients with COVID-19, but the recommendations in clinical guidelines differ; some suggest their use, others against.

Objectives: We aim to assess the effects of low-dose intravenous hydrocortisone on the number of days alive without life-support in adult patients with COVID-19 and severe hypoxia.

Design: Multicentre, parallel-group, centrally randomised, stratified, blinded, clinical trial.

Population: Adult patients with documented COVID-19 receiving at least 10 L/min of oxygen independent of delivery system OR mechanical ventilation.

Experimental intervention: Continuous IV infusion of hydrocortisone 200 mg daily will be given for 7 days in addition to standard care.

Control intervention: Continuous IV infusion of matching placebo (0.9% saline) will be given in addition to standard care (no corticosteroids).

Outcomes: The primary outcome is days alive without life support (i.e. mechanical ventilation, circulatory support, or renal replacement therapy) at day 28. Secondary outcomes are serious adverse reactions (i.e. anaphylactic reaction to hydrocortisone, new episode of septic shock, invasive fungal infection or clinically important gastrointestinal bleeding); days alive without life support at day 90; days alive and out of hospital at day 90; all-cause mortality at day 28, day 90 and 1 year; and health-related quality of life at 1 year.

Sample size: A total of 1000 participants will be randomised in order to detect a 15% relative reduction in 28-day mortality combined with a 10% reduction in time on life support among the survivors with a power of 85%.

03

Conditions studied

  • Covid-19
  • Hypoxia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All the following criteria must be fulfilled:

  • Aged 18 years or above AND
  • Confirmed SARS-CoV-2 (COVID-19) requiring hospitalisation AND
  • Use of one of the following:

    • Invasive mechanical ventilation OR
    • Non-invasive ventilation or continuous use of continuous positive airway pressure (CPAP) for hypoxia OR
    • Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system

Exclusion criteria

Exclusion Criteria:

We will exclude patients who fulfil any of the following criteria:

  • Use of systemic for any other indication than COVID-19
  • Invasive mechanical ventilation for more than 48 hours
  • Invasive fungal infection
  • Fertile woman (\< 60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG
  • Known to hydrocortisone
  • A patient for whom the clinical team has decided not to use invasive mechanical ventilation
  • Previously randomised into the COVID STEROID trial
  • not obtainable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Hydrocortisone

    Continuous intravenous infusion of hydrocortisone 200 mg over 24 hours (total 104 ml). The trial intervention will be given in addition to standard care. If continuous intravenous infusion is not possible, we will allow the use of bolus injection of the trial medication (50 mg (10 ml) every 6 hours).

    Drug: Hydrocortisone

  • Placebo comparator
    Isotonic Saline

    Continuous intravenous infusion of matching isotonic saline (0.9%) placebo at a dose volume of 104 ml over 24 hours in addition to standard care (no corticosteroid treatment). If continuous intravenous infusion is not possible, we will allow the use of bolus injection of matching saline placebo (10 ml every 6 hours).

    Drug: Sodium Chloride 9mg/mL

Interventions

  • Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days

    Also known as: Solu-cortef

  • DrugSodium Chloride 9mg/mL

    Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days

    Also known as: Isotonic saline

06

What researchers measure

Primary outcomes

  1. Days alive without life support at day 28

    Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28

    Time frame: Day 28 after randomisation

Secondary outcomes

  1. All-cause mortality at day 28

    Death from all causes

    Time frame: Day 28 after randomisation

  2. Days alive without life support at day 90

    Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90

    Time frame: Day 90 after randomisation

  3. All-cause mortality at day 90

    Death from all causes

    Time frame: Day 90 after randomisation

  4. Number of participants with one or more serious adverse reactions

    Defined as new episodes of septic shock, invasive fungal infection, clinically important GI bleeding or anaphylactic reaction

    Time frame: Day 14 after randomisation

  5. Days alive and out of hospital at day 90

    Number of days alive and out of hospital not limited to the index admission

    Time frame: Day 90 after randomisation

  6. All-cause mortality at 1 year after randomisation

    Death from all causes

    Time frame: 1 year after randomisation

  7. Health-related quality of life at 1 year

    Assessed by EQ-5D-5L

    Time frame: 1 year after randomisation

  8. Health-related quality of life at 1 year

    Assessed by EQ-VAS

    Time frame: 1 year after randomisation

07

Study locations

14 sites
  • Aarhus University Hospital - Dept of Intensive care
    Aarhus, Denmark
  • Rigshospitalet
    Copenhagen, DK-2100, Denmark
  • Dept of Infectious diseases, Rigshospitalet
    Copenhagen, Denmark
  • Herlev Hospital - Dept. of Intensive Care
    Herlev, Denmark
  • North Zealand Hospital
    Hillerød, Denmark
  • Hvidovre Hospital - Dept of Infectious diseases
    Hvidovre, Denmark
  • Hvidovre Hospital - Dept of Intensive Care
    Hvidovre, Denmark
  • Hvidovre Hospital - Dept of Pulmonary Medicine
    Hvidovre, Denmark
  • Kolding Hospital
    Kolding, Denmark
  • Køge Hospital
    Køge, Denmark
  • Dept of Intensive Care, Odense University Hospital
    Odense, Denmark
  • Roskilde Hospital
    Roskilde, Denmark
  • Slagelse Hospital
    Slagelse, Denmark
  • Viborg Hospital
    Viborg, Denmark
08

References and documents

Publications

  • Munch MW, Granholm A, Kjaer MN, Aksnes TS, Solling CG, Christensen S, Perner A. Long-term mortality and health-related quality of life in the COVID STEROID trial. Acta Anaesthesiol Scand. 2022 Apr;66(4):543-545. doi: 10.1111/aas.14029. Epub 2022 Feb 3. No abstract available. PubMed 35067914 ↗
  • Munch MW, Meyhoff TS, Helleberg M, Kjaer MN, Granholm A, Hjortso CJS, Jensen TS, Moller MH, Hjortrup PB, Wetterslev M, Vesterlund GK, Russell L, Jorgensen VL, Kristiansen KT, Benfield T, Ulrik CS, Andreasen AS, Bestle MH, Poulsen LM, Hildebrandt T, Knudsen LS, Moller A, Solling CG, Brochner AC, Rasmussen BS, Nielsen H, Christensen S, Strom T, Cronhjort M, Wahlin RR, Jakob SM, Cioccari L, Venkatesh B, Hammond N, Jha V, Myatra SN, Jensen MQ, Leistner JW, Mikkelsen VS, Svenningsen JS, Laursen SB, Hatley EV, Kristensen CM, Al-Alak A, Clapp E, Jonassen TB, Bjerregaard CL, Osterby NCH, Jespersen MM, Abou-Kassem D, Lassen ML, Zaabalawi R, Daoud MM, Abdi S, Meier N, la Cour K, Derby CB, Damlund BR, Laigaard J, Andersen LL, Mikkelsen J, Jensen JLS, Rasmussen AH, Arnerlov E, Lykke M, Holst-Hansen MZB, Tostesen BW, Schwab J, Madsen EK, Gluud C, Lange T, Perner A. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: The COVID STEROID randomised, placebo-controlled trial. Acta Anaesthesiol Scand. 2021 Nov;65(10):1421-1430. doi: 10.1111/aas.13941. Epub 2021 Sep 20. PubMed 34138478 ↗

Related links

Individual participant data

Plan to share: Yes — Fully de-identified IPD will be shared after the approval by the the trial management committee

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit

Access criteria: Contact to the trial management committee

Data sharing details ↗ · www.cric.nu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Sep 2020, 4 months.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 4 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2020
First posted
Apr 16, 2020
StartActual
Apr 17, 2020
Primary completionActual
Sep 10, 2020
CompletionActual
Sep 8, 2021
Last update
Sep 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04348305
Lead sponsor
Scandinavian Critical Care Trials Group
Collaborators
Rigshospitalet, Denmark, Copenhagen Trial Unit, Center for Clinical Intervention Research, University of Copenhagen, Aarhus University Hospital
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
Apr 17, 2020
Primary completion
Sep 10, 2020
Completion
Sep 8, 2021
Last update
Sep 21, 2021

Study contacts

Anders Perner, MD, PhD
study chair · Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydrocortisone

Start the discussion